Evidence map›Paper›PMID 30992552›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2019

Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result.

Emma R Leof, Xuan Zhu, Kari G Rabe, Jennifer B McCormick, Gloria M Petersen, Carmen Radecki Breitkopf

Open access · bronzeAbstract read
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Emma R LeofInfectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, MN, USA.
Xuan ZhuDepartment of Health Sciences Research, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.
Kari G RabeDepartment of Health Sciences Research, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.
Jennifer B McCormickDepartment of Humanities, College of Medicine, Pennsylvania State University, Hershey, PA, USA.
Gloria M PetersenDepartment of Health Sciences Research, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.
Carmen Radecki BreitkopfDepartment of Health Sciences Research, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN, USA. radeckibreitkopf.carmen@mayo.edu.
Mayo Clinic · USMinnesota Department of Health · USPennsylvania State University · US

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
Pancreatic Cancer Genetic Epidemiology Consortium (PACGENE)R01CA097075 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2002 to 2012
$15.8M
Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindredsR01CA208517 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO, LI, HU · 2016 to 2020
$2.9M
Disclosing Genomic Incidental Findings in a Cancer Biobank: An ELSI ExperimentR01CA154517 · NCI · MAYO CLINIC ROCHESTER · PI KOENIG, BARBARA A., PETERSEN, GLORIA M. · 2011 to 2015
$2.7M
NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA097075NCI NIH HHS R01 CA154517NCI NIH HHS R01 CA208517
6 · The paper itself

Abstract

purposeThis study examined whether participants who learned research results related to a germline CDKN2A variant known to be associated with increased risk of pancreatic cancer and malignant melanoma would pursue confirmatory testing and cancer screening, share the genetic information with health care providers and family, and change risk perceptions.

methodsParticipants were pancreas research registry enrollees whose biological sample was tested in a research laboratory for the variant. In total, 133 individuals were invited to learn a genetic research result and participate in a study about the disclosure process. Perceived cancer risk, screening intentions, and behaviors were assessed predisclosure, immediately postdisclosure, and six months postdisclosure.

resultsEighty individuals agreed to participate and 63 completed the study. Immediately postdisclosure, carriers reported greater intentions to undergo pancreatic cancer and melanoma screening (p values ≤0.024). Seventy-three percent of carriers (47.5% noncarriers) intended to seek confirmatory testing within six months and 20% (2.5% noncarriers) followed through. All participants shared results with ≥1 family member. More carriers shared results with their health care provider than noncarriers (p = 0.028).

conclusionRecipients of cancer genetic research results may not follow through with recommended behaviors (confirmatory testing, screening), despite stated intentions. The research result disclosure motivated follow-up behaviors among carriers more than noncarriers.

Indexed as

AdultAgedCyclin-Dependent Kinase Inhibitor p16DisclosureFamilyFemaleGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingHealth Knowledge, Attitudes, PracticeHumansMaleMelanomaMiddle AgedPancreatic NeoplasmsRisk FactorsCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16cancer screeninggenetic research resultmelanomapancreatic cancerrisk perception

Identifiers

PMID30992552
PMCPMC6800778
OpenAlexW2939628338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.